I en sammenlignende undersøgelse med topotecan og paclitaxel hos patienter tidligere behandlet for ovariecancer med platinbaseret kemoterapi (n = 112 og n = 114, respektivt), var responsraten (95% CI) 20, 5% (13%, 28%) versus 14% (8%, 20%) og mediantiden til progression var 19 uger versus 15 uger (risiko ratio 0, 7 [0, 6; 1, 0] for topotecan og paclitaxel respektivt.
In a comparative study of topotecan and paclitaxel in patients previously treated for ovarian carcinoma with platinum based chemotherapy (n = 112 and 114, respectively), the response rate (95% CI) was 20.5% (13%, 28%) versus 14% (8%, 20%) and median time to progression 19 weeks versus 15 weeks (hazard ratio 0.7 [0.6, 1.0]), for topotecan and paclitaxel, respectively.